J. Strnad

发表

Molecular cloning and characterization of a human adenocarcinoma/epithelial cell surface antigen complementary DNA.

J. R. Sportsman, G. Gamboa, J. Sharp, 1989, Cancer research.

Identification of a critical aspartate residue in transmembrane domain three necessary for the binding of somatostatin to the somatostatin receptor SSTR2.

J. Strnad, J. Hadcock, 1995, Biochemical and biophysical research communications.

Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain

K. McIntyre, C. Chaudhry, L. Salter-Cid, 2019, Science Translational Medicine.

Pharmacological characterization of the rat A2a adenosine receptor functionally coupled to the yeast pheromone response pathway.

M. Pausch, J. Strnad, J. Hadcock, 1996, Molecular pharmacology.

NEMO binding domain of IKK‐2 encompasses amino acids 735–745

C. Mapelli, D. Riexinger, R. Ryseck, 2006, Journal of molecular recognition : JMR.

In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states.

L. Butler, N. Layman, P. Riedl, 1988, Cancer research.

Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2).

S. Spergel, K. McIntyre, J. Tokarski, 2019, Journal of medicinal chemistry.

349 - BMS-986165 is a Highly Potent and Selective Allosteric Inhibitor of TYK2, Blocks Il-12, IL-23 and type I Interferon Signaling and Provides for Robust Efficacy in Preclinical Models of Inflammatory Bowel Disease

J. Chen, C. Chaudhry, K. Gillooly, 2018 .

Identification and characterization of novel somatostatin antagonists.

M. Pausch, J. Strnad, J. Hadcock, 1996, Molecular pharmacology.

Periodic, Partial Inhibition of IκB Kinase β-Mediated Signaling Yields Therapeutic Benefit in Preclinical Models of Rheumatoid Arthritis

K. McIntyre, Laishun Chen, W. Pitts, 2009, Journal of Pharmacology and Experimental Therapeutics.

Rat somatostatin receptor type 1 couples to G proteins and inhibition of cyclic AMP accumulation.

J. Strnad, C. Eppler, J. Hadcock, 1994, Molecular pharmacology.

Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling.

J. Tokarski, D. Xie, N. Araníbar, 2017, MedChemComm.

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.

S. Spergel, K. McIntyre, D. Shuster, 2019, Journal of medicinal chemistry.

Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors.

James Lin, K. McIntyre, J. Tokarski, 2019, ACS medicinal chemistry letters.

BMS-345541 Is a Highly Selective Inhibitor of IκB Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-κB-dependent Transcription in Mice*

James R. Burke, John F. MacMaster, K. McIntyre, 2003, The Journal of Biological Chemistry.

BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice.

K. McIntyre, Y. Qiu, F Christopher Zusi, 2003, The Journal of biological chemistry.

IκB kinase inhibitors for treating autoimmune and inflammatory disorders: potential and challenges

J. Strnad, J. Burke, 2007 .

A Novel Peptidylarginine Deiminase 4 (PAD4) Inhibitor BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma

J. Strnad, D. Vogl, James J. Burke, 2020, Molecular Cancer Therapeutics.

[10] Somatostatin receptor coupling to G proteins

J. Strnad, J. Hadcock, 1996 .

The rat SSTR2 somatostatin receptor subtype is coupled to inhibition of cyclic AMP accumulation.

J. Strnad, C. Eppler, J. Hadcock, 1993, Biochemical and biophysical research communications.

Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2.

James Lin, K. McIntyre, D. Shuster, 2020, Journal of medicinal chemistry.

A design approach to the structural analysis of interleukin‐2

F. Cohen, K. Smith, J. Strnad, 1988, Journal of molecular recognition : JMR.

Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.

Andrew Tebben, Qian Ruan, Neha Surti, 2014, Bioorganic & medicinal chemistry letters.

IkappaB kinase inhibitors for treating autoimmune and inflammatory disorders: potential and challenges.

J. Strnad, J. Burke, 2007, Trends in pharmacological sciences.

In vivo selection of human tumor cells resistant to monoclonal antibody-Vinca alkaloid immunoconjugates.

J. J. Starling, J. Strnad, T. Bumol, 1990, Cancer research.

Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2).

S. Spergel, K. McIntyre, J. Tokarski, 2019, Journal of medicinal chemistry.